CLINICAL OUTCOME OF PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH BARE-METAL VERSUS DRUG-ELUTING STENTS: INSIGHTS FROM THE AFCAS REGISTRY  by Puurunen, Marja Kaarina et al.
TCT@ACC-i2: The Interventional Learning Pathway
A1681
JACC April 1, 2014
Volume 63, Issue 12
clinicAl outcoMe of PAtients With AtriAl fibrillAtion unDergoing PercutAneous 
coronAry interVention With bAre-MetAl Versus Drug-eluting stents: insights froM the 
AfcAs registry
Moderated Poster Contributions
Hall C
Monday, March 31, 2014, 10:15 a.m.-10:30 a.m.
Session Title: TCT@ACC-i2: The Interventional Learning Pathway Moderated Posters V
Abstract Category: 38. TCT@ACC-i2: Complex Patients/Comorbidities
Presentation Number: 2117M-367C
Authors: Marja Kaarina Puurunen, Tuomas Kiviniemi, Axel Schlitt, Andrea Rubboli, Pasi Karjalainen, Fausto Biancari, Wail Nammas, Paulus 
Kirchhof, Gregory Lip, Juhani Airaksinen, Finnish Red Cross Blood Service, Helsinki, Finland, Turku University Hospital Heart Center, Turku, Finland
background: Current guidelines prefer the use of bare-metal stents (BMS) to drug-eluting stents (DES) in patients with atrial fibrillation (AF) 
undergoing percutaneous coronary intervention (PCI) due to potentially increased risk of bleeding. We sought to explore the 12-month adverse event 
rates of patients treated with BMS versus DES in the European prospective, multicenter AFCAS (Atrial Fibrillation undergoing Coronary Artery Stenting) 
registry.
Methods: Out of 929 patients enrolled in the AFCAS registry, 673 (72.4%) received BMS, and 220 (23.7%) received at least one DES. Major 
adverse cardiac and cerebrovascular events (MACCE) were defined as a composite of all-cause mortality, any non-fatal MI, any revascularization, 
definite/probable stent thrombosis, transient ischemic attack (TIA) or stroke, and peripheral arterial embolism. Bleeding events were defined 
according to the Bleeding Academic Research Consortium (BARC) and stent thrombosis (ST) as definite/probable according to ARC criteria.
results: Patients treated with DES were more often diabetic, had longer stent length and more often prior ischemic events, whereas patients 
treated with BMS had more often heart failure, and were more likely to present with acute ST-segment-elevation MI. The median duration of 
clopidogrel therapy was significantly shorter in patients treated with BMS (1.0 [5] versus 12 [6] months, p<0.001). At 12-month follow-up, the rates 
of MACCE (22.0% vs. 19.5%, p=0.51), any bleeding event (19.5% vs. 15.0%, p=0.16) and target vessel revascularization (7.7% vs. 8.2%, p=0.89) 
were comparable between the groups. ST was more frequent in the BMS group (1.9 vs. 0%, respectively, p=0.046); and nearly half (46.7%) of them 
occurred <30 days after the index procedure. Anemia (HR 3.83 95%CI 1.16-12.7, p=0.028), diabetes (HR 4.39, 95%CI 1.28-15.0, p=0.018) and 
previous gastrointestinal bleeding (HR 11.7, 95%CI 2.34-58.2, p=0.003) were independent predictors of ST in Cox regression model.
conclusions: In this real-world registry of patients with AF undergoing PCI the use of DES was not associated with increased bleeding risk 
compared to BMS. ST was rare and the rate of MACCE was comparable between groups.
